Drug Trial Radar · NCT04489108
Tranexamic Acid for Acute Upper Gastrointestinal Bleed in Cirrhosis
Last checked: Nov 19, 2026Latest source record: Jan 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
600
Planned (sponsor's estimate)
Start
Nov 5, 2020
Primary completion
Apr 30, 2022
Study completion Apr 30, 2022
Sponsor
- Lead sponsor
- Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 28, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The management of acute upper gastrointestinal bleeding (UGIB) is challenging in patients with cirrhosis, as it is responsible for severe complications and high mortality rates. Fibrinolytic activity of the epithelial surfaces and of the submucosal blood vessels may interfere with hematemesis and even delay healing of ulcers. Tranexamic acid (TXA) may help control the bleeding by counterbalancing cirrhosis-related hyperfibrinolysis. Still, there is a lack of unbiased data to conclude on its efficacy. Tranexamic Acid in patients with acute Upper Gastrointestinal bleed have been shown to prevent re bleed in few studies when combined with standard medical management (which generally comprises of initial fluid resuscitation, intravenous PPI , splanchnic vasoconstrictors, blood transfusions and coagulopathy corrections as per lab parameters) but no randomized placebo controlled trial has been done. The aim of this study is to evaluate the efficacy of TXA in the early treatment of acute UGIB as compared to placebo in patients with cirrhosis.
Conditions
- Liver Cirrhosis
Interventions
Tranexamic acidDrug
Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours
Standard Medical TreatmentOther
Standard Medical Treatment
PlaceboOther
isotonic solution (saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients developing five-day treatment failure in both the groupsTime frame: 5 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.